VALOR Study Topline Results - The VALOR study of Brepocitinib in Dermatomyositis (DM) succeeded with highly significant, robust, and consistent data across primary and all key secondary endpoints[18] - A consistent dose response was observed between 15 mg and 30 mg, establishing 30 mg as the optimal dose[18] - Brepocitinib 30 mg showed a mean TIS of 46.5, a delta of >15 points (p=0.0006) relative to placebo at week 52 (TIS of 31.2)[18] - Over two-thirds (68%) of brepocitinib 30 mg patients experienced at least a moderate response (TIS40), compared to 44.3% on placebo[37,61] - Nearly half (46.1%) of brepocitinib 30 mg patients experienced a major response (TIS60), compared to 26.4% on placebo[37,61] - Median time to a TIS40 response was approximately 2 months[18] - At week 52, 54.3% of patients achieving TIS40 Response + ≤2.5 mg OCS on Brepocitinib 30mg vs 26.6% on Placebo[61] - At week 52, CDASI-A change from baseline at -11.7 for Brepocitinib 30mg vs -7.0 for Placebo[61] Safety and Regulatory - The safety profile of Brepocitinib 30 mg in VALOR was consistent with prior clinical studies[18] - FDA filing is planned for the first half of 2026[18]

Financial Performance - Total revenues for Q4 FY2025 were RMB 6178 million[8], with Pop Toy Business contributing RMB 658 million[8] - Adjusted Net Income for Q4 FY2025 was RMB 1112 million[8], a YoY decrease of 426%[8] - The company reported Cash and Cash Equivalents, Restricted Cash and Short-term Investments of RMB 10409 million[8] Pop Toy Industry and Letsvan Acquisition - The global toy market grew at a CAGR of 52% from RMB 6312 billion in 2019 to RMB 7731 billion in 2023[9], and is expected to reach RMB 9937 billion in 2028[9] - China's blind box market is projected to reach RMB 58 billion by 2025, accounting for 65% of the global share[10] - Letsvan was acquired and fully consolidated, focusing on IP commercialization and targeting the younger generation[6, 12] Strategic Initiatives and Partnerships - Letsvan became a core marketing partner of the 2025 China Open, launching 10 co-branded WAKUKU x China Open products[18] - Strategic distribution partnerships include a wholesale network of over 10000 retail stores domestically and expansion to over 20 countries internationally[28] - Online GMV in China Market achieved RMB 18M+ in August 2025, representing 9x April's level[29] IP Portfolio and Product Development - The company has a portfolio of 15 IPs, including 11 self-owned, 2 exclusive licensed, and 2 non-exclusive[8, 39] - The company focuses on data-driven IP incubation, end-to-end supply chain management, and omni-channel distribution network[13]

JP Morgan US All Stars Conference Joe Hinrichs President & Chief Executive Officer Sean Pelkey Executive Vice President & Chief Financial Officer 9.17.2025 Forward Looking Disclosure This information and other statements by the company may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to, among other items: projections and estimates of earnings, revenues, margins, volumes, rates, cost-savings, expenses, taxes, liquidity, capital expenditur ...

Hereditary Angioedema (HAE) - Navenibart - Navenibart aims to be the first-choice therapy for preventative treatment of HAE, with potential for quarterly (Q3M) and semi-annual (Q6M) administration[15, 6] - Phase 1b/2 data suggests Navenibart's efficacy could match or exceed existing treatments while reducing treatment burden[16] - The Phase 3 program, including ALPHA-ORBIT and ORBIT-EXPANSE trials, is designed to support global registration, with topline data expected in early 2027[18] - ALPHA-STAR and SOLAR trials showed a mean attack rate reduction of 91-95% across all doses, with an overall mean of 92%[24] - The ALPHA-SOLAR trial demonstrated consistent efficacy with a longer median follow-up of 9.1 months, showing a 92% attack rate reduction from baseline[28, 29] - Market research indicates that offering both Q3M and Q6M dosing options could increase market adoption, with 53% of patients initiating preventative therapy and 46% switching preventative therapy preferring Q3M & Q6M options[32] Atopic Dermatitis (AD) - STAR-0310 - STAR-0310 targets the OX40 pathway and has the potential to become the first-choice OX40 therapy for Atopic Dermatitis[45] - The U S commercial opportunity for moderate-to-severe AD is projected to reach $22 billion by 2030[35, 36, 44] - Phase 1a data demonstrates a best-in-class 68-day half-life, supporting potential for every-six-month dosing[51, 71, 77] - Phase 1a data showed broad and durable pharmacodynamic effect across Type 1, 2, and 3 inflammation, with maximal suppression achieved within one week and sustained for at least 16-20 weeks[63, 68, 77]

Growth & Financials - Workday expects to add $1 billion in net new subscription revenue each year from FY23 to FY26E, reaching $8.8 billion in FY26E[46] - The company anticipates a Non-GAAP operating margin of 29% in FY26E, a 3 percentage point increase from 20.1% in FY23[49] - Workday projects stock-based compensation expense as a percentage of revenue to be approximately 17% in FY26E, a decrease of ~1 percentage point from 21% in FY23[52] - The company aims for a subscription revenue CAGR of 13%-14% through FY28 and a Non-GAAP operating margin of ~35% in FY28[55] - Workday intends to execute $5 billion in share repurchases through FY27[55, 56] AI & Product Innovation - Over 75 million users are under contract on the Workday platform[23, 24, 149] - More than 75% of net-new customer wins include one or more AI products[26] - Over 30% of customer expansions include one or more AI products[26] - Emerging Agentic AI SKUs are experiencing growth exceeding 200% year-over-year[33, 35] Market Expansion - Medium Enterprise customers account for over 50% of new customer ACV[44, 174] - The company is seeing ~20% FINS+ subscription revenue growth[44]

Company Overview - MIND Technology, Inc is a leading provider of marine technology[1,5] - The company focuses on three broad markets within the marine industry[6] - Seamap unit is a leading supplier to the seismic exploration and survey industries[7] Financial Performance and Strategy - MIND transformed for profitable growth by selling Klein Sonar Unit in August 2023 and streamlining operations[14] - The company eliminated outstanding debt and recapitalized by converting all preferred stock to common stock[15] - The firm backlog was $128 million as of July 31, 2025[21] - Approximately 68% of revenue in the first half of fiscal year 2026 is from recurring after-market (spares, etc)[39] - For the six months ended July 31, 2025, MIND Technology reported revenues of $21463 thousand and a net income of $959 thousand[69,72] Market and Industry - Global spending on exploration should average $22 billion per year in real terms over the next five years[11] - Global capital expenditure on subsea facilities is set for a 10% compound annual growth rate from 2024 to 2027[12]

Transaction Overview - NBHC will acquire Vista Bancshares, Inc in a deal valued at $369 million[10] - The deal structure involves approximately 80% stock and 20% cash consideration[10] - Vista shareholders will receive 31161 shares of NBHC and $3162 in cash for each common share of Vista Bancshares, Inc[10] - Pro forma ownership will be approximately 84% NBHC and 16% Vista[10] Strategic Rationale - The acquisition enhances NBHC's financial performance with an expected EPS accretion of approximately 17% in 2026[14] - The transaction is expected to improve NBHC's 2026 Return on Average Tangible Common Equity (ROATCE) by 350bps+[14] - The acquisition accelerates NBHC's growth strategy in Texas, a demographically attractive banking market with a projected 5-year population growth of 56%, more than 2x the national average[14] - Vista's strong loan growth CAGR of 21% since 2021 enhances NBHC's growth profile[14] Vista Bancshares Overview - Vista Bancshares, Inc has $21 billion in assets, $19 billion in loans, and $2 billion in deposits as of Q2 2025[16] - Vista's Net Income is $68 million[16] - 73% of Vista deposits are located in Dallas[18]

Cautionary Statement on Forward-Looking Information… Certain information contained or incorporated by reference in this presentation, including any information as to our strategy, projects, plans or future financial or operating performance, constitutes "forward-looking statements". All statements, other than statements of historical fact, are forward-looking statements. The words "expect", "target", "plan", "guidance", "ramp up", "on track", "project", "continue", "additional", "growth", "expand", "potenti ...

Financial Performance & Targets - The company aims for a high-single-digit percentage revenue CAGR and a mid-teens percentage adjusted EPS CAGR since FY22[57, 59] - Ralph Lauren has generated over $2 billion in free cash flow and achieved a 111% adjusted ROIC since FY22[64] - The company projects mid-single-digit percentage revenue CAGR through FY28, with operating margin expansion[94] - The company's revenue target for FY28 is $7.1 billion[765] - The company anticipates a gross margin expansion annually through FY28[794] - The company projects adjusted operating margin expansion of 100 to 150bps[807] Brand & Market Position - Ralph Lauren's brand market share is less than 2% of a $400 billion+ total market value[73, 71] - Ralph Lauren is the 1 most trusted fashion brand with the most loyal customers in the industry[77, 79] - The company has acquired over 16 million new customers[274] Regional Growth - APAC is the company's fastest-growing region, with a revenue CAGR of +17% and a double-digit percentage AUR growth since FY22[450, 451] - China has delivered a +24% revenue CAGR and added over 100 new stores since FY22[456, 458] - EMEA has achieved a +10% revenue CAGR and a +30% AUR increase since FY22[521]

Financial Performance - Q4 2025 - Net sales reached $8.5 billion, a 6.9% increase compared to Q4 2024, driven by market outperformance[6] - Organic growth contributed 5.8% and acquisitions added 1.1% to the net sales growth[6] - Adjusted operating profit was $972 million, up 13.4% from Q4 2024, with an adjusted operating margin of 11.4%, a 60 bps increase[6] - Adjusted diluted EPS increased by 16.8% to $3.48[6] Financial Performance - FY2025 - Net sales for FY2025 totaled $30.8 billion, a 3.8% increase compared to FY24[13] - Adjusted operating profit was $2.8 billion, a 0.6% increase compared to FY24[13] - Adjusted diluted EPS reached $9.94, a 2.6% increase compared to FY24[13] - The company generated $1.9 billion in operating cash flow[13] Capital Deployment & Balance Sheet - Capital deployment included $483 million, with 4 acquisitions completed during the quarter, share repurchases of $189 million, and dividends of $165 million[6] - The balance sheet remains strong, with net debt to adjusted EBITDA at 1.1x[6] - Share repurchases completed during the fiscal year totaled $948 million, with approximately 5.0 million shares repurchased[36] - The share repurchase program has an outstanding balance of approximately $1.0 billion[36] Market Performance & Outlook - US net sales grew by 7.1% in Q4 2025, compared to a 1.3% growth in Q4 2024[8] - For FY2025, the company estimates a market decline of approximately 2% in the US, while Ferguson US organic revenue grew by 3.2%[16] - Calendar year 2025 guidance includes mid-single digit growth in net sales and an adjusted operating margin between 9.2% and 9.6%[39]